Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024

Rhea-AI Summary

Lumos Pharma (NASDAQ:LUMO) announced the acceptance of an abstract for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (SLEP 2024) in Santiago, Chile. The abstract, titled 'LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials', will be presented as an e-poster on September 13, 2024. This presentation will feature an updated analysis of data from Lumos Pharma's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials, focusing on their therapeutic candidate for rare diseases.

Positive

• Abstract accepted for presentation at a significant medical meeting (SLEP 2024)
• Presentation includes updated analysis of Phase 2 clinical trial data
• Research focuses on LUM-201's potential in treating Pediatric Growth Hormone Deficiency

Negative

• None.

AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile.

Abstract Presentation: Friday, September 13^th – E-poster Session 2 – 1:15-2:30PM Local Time

• Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials (Rossana Román, MD, et al)
  

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What is the title of Lumos Pharma's (LUMO) abstract accepted for SLEP 2024?

The accepted abstract is titled 'LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials'.

When and where will Lumos Pharma (LUMO) present its abstract at SLEP 2024?

Lumos Pharma will present its abstract on Friday, September 13, 2024, during the E-poster Session 2 from 1:15-2:30 PM local time at SLEP 2024 in Santiago, Chile.

What clinical trials are featured in Lumos Pharma's (LUMO) SLEP 2024 presentation?

The presentation features updated analysis of data from Lumos Pharma's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials.

What is the focus of Lumos Pharma's (LUMO) research presented at SLEP 2024?

The research focuses on LUM-201's potential to restore growth hormone secretion and promote growth in moderate Pediatric Growth Hormone Deficiency (PGHD).